As patients, physicians, dialysis providers, and payers search for more favorable outcomes in patients with end-stage renal disease (ESRD), alternative dialysis regimens have gained popularity. Among these therapies are dialysis treatments that are performed more frequently, for longer periods of time, and/or at the patient’s home.
Despite current therapies, renal cell carcinoma (RCC) is often lethal. Many factors influence outcomes, including stage, grade, subtype, necrosis, and molecular attributes. Prognosis can be difficult to determine. Comprehensive staging strategies that incorporate multiple patients and tumor factors are necessary to predict survival accurately and optimize research strategies. Recently designed algorithms allow for convenient and up-to-date estimates of outcome in this rapidly evolving field.
